TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Percutaneous Immunostimulating Interstitial Laser Thermotherapy in Pancreatic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A diagnosis of non-resectable pancreatic adenocarcinoma by form of either locally advanced disease (stage II-III) or of stage IV disease with hepatic metastasis (staging according to UICC 2009)~* Locally advanced disease shall have a lesion diameter less than 4cm~* If stage IV disease, the patient shall have only liver metastasis, with less than 5 in number, each one less than 4 cm in diameter~* The patient is a candidate for standard chemotherapy (as described at point 5.1)~* Age between 18 and 80 years, males and females~* Anticipated compliance with treatment and follow-up~* Have given informed verbal and written consent to participation in the trial~* Have stable and adequate haematologic, renal and hepatic functions:~  1. Hemoglobin ≥9 g/dL~ 2. Platelet count ≥75 x 109/L~ 3. International normalized ratio (INR) ≤1.7~ 4. WBC count ≥2 x 109/L~ 5. Absolute neutrophil count (ANC) ≥1 x 109/L~ 6. Albumin ≥2.8 g/dL, total bilirubin ≤3.0 mg/dL (51.3 μmol/L); ALT, AST ≤5 times upper limit of normal (ULN)~ 7. Serum chemistries sodium, potassium, and calcium within normal limits (WNL)~ 8. Serum creatinine \<2.0 mg/dL or creatinine clearance \>60 mL/min according to Cockroft-Gault formula~* At least a part of the tumour can be treated with imILT without damage to adjacentvital structures~* Have an ECOG performance status \<2 (Karnofsky\> 60%)~Exclusion Criteria:~* HIV 1 or 2 positive~* Active autoimmune disease which is judged to reduce an anti-tumour immune response~* Pregnancy or breast feeding~* Have known bleeding disorder that cannot be managed accordingly with the protocol rules, such severe acute or chronic liver failure, other genetic blood diseases not properly managed prior to treatment or other any disease treated with anticoagulant or anti-platelet medication that cannot be interrupted prior to treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- imILT treatment (Type: EXPERIMENTAL): Immunostimulating Interstitial Laser Thermotherapy (imILT)
- Standard chemotherapy treatment (Type: ACTIVE_COMPARATOR): This study arm recieves chemotherapy treatment as standard care at the clinical study site.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study on the Efficacy of Phenytoin in the Prophylaxis of Seizures of Patients With Pneumococcal Meningitis at Least 50 Yrs Old.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Adult patients \> or = 50 years old.~Diagnosed of pneumococcal meningitis due to clinical characteristics plus a positive CSF Gram stain and/or a detection of pneumococcal antigen or PCR~or~Suspected pneumococcal meningitis since it is an episode related to otitis, pneumonia, sinusitis or pericranial fistula or in patients with known risk factors such as myeloma or splenectomy.~Exclusion Criteria:~To have seizures prior to arrive to the hospital or the inclusion in the study.~Pregnancy or breastfeeding.~To have conduction abnormalities in ECG.~History of allergy or intolerance to phenytoin.~Patients with meningitis as a complication of neurosurgical procedures.~Epileptic patients taking usually anticonvulsivants.~Refusal by the patient or family to participate and/or to sign the informed consent.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- phenytoin prophylaxis (Type: EXPERIMENTAL): Patients with suspected or proven pneumococcal meningitis are allocated to receive phenytoin prophylaxis or placebo to avoid seizures during the 10 days of antibiotic therapy starting after the antibiotic therapy
- placebo (Type: PLACEBO_COMPARATOR): placebo vials and pills labeled as phenytoin prophylaxis vials and pills

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* - Patients (≥18 years of age) admitted to the hospital with confirmed COVID-19 and not needing admission to MC or ICU~* Patient has moderate to severe COVID-19. This will be defined as patients with NEWS-2 score ≤ 5.~* Willing and able to give written informed consent~Exclusion Criteria:~* - Severe Covid-19 defined as NEWS-2 score \>5 or admission to the ICU needing ventilation or pressure support.~* Contra-indications for hydroxychloroquine or chloroquine~* Unable to take oral medication (chloroquine and hydroxychloroquine can be administered through tube feeding which is considered oral administration)~* Identified allergies to 4-aminoquinoline~* Severe diseases of the blood system~* 6-phosphate dehydrogenase deficiency~* History of acute myocardial infarction, unstable angina pectoris, severe arrhythmia (frequent ventricular, ventricular tachycardia, ventricular fibrillation) in recent 6 months; New York Heart Association (NYHA) level III-IV~* Known corrected QT interval (QTc) ≥ 500ms.~* Uncorrected severe hypokalaemia (\< 2,5 mmol/l) or uncorrected severe hypomagnesemia (\< 0.6 mmol/l)~* Pancreatitis~* Refusal to participate expressed by patient or legally authorized representative if they are present

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 110 Years
- Healthy Volunteers: t

Study Arms:
- chloroquine (Type: ACTIVE_COMPARATOR): 1. Supportive care + chloroquine base arm: loading dose 600mg, followed by 300mg 12 hours later, followed by 300mg bid for 4 days; total treatment duration of 5 days
- hydroxychloroquine (Type: ACTIVE_COMPARATOR): 2. Supportive care + hydroxychloroquine arm: loading dose 400mg bid, followed by 200mg bid for 4 days; total treatment duration of 5 days.
- Supportive care only (Type: NO_INTERVENTION): 3. Supportive care only.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Vaccine Therapy in Treating Patients With Stage IIB, Stage III, or Stage IV Colorectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of colorectal cancer~  * Stage IIB, III, or IV disease~* HLA-A2- or -A3-positive~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* ECOG 0-1~Life expectancy~* Not specified~Hematopoietic~* Absolute neutrophil count \> 1,000/mm\^3~* Hemoglobin \> 9 g/dL~* Platelet count \> 100,000/mm\^3~Hepatic~* Liver function tests ≤ 2.5 times upper limit of normal (ULN)~Renal~* Creatinine ≤ 1.5 times ULN~Cardiovascular~* No New York Heart Association class III or IV heart disease~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No known or suspected allergies to any component of the study drug~* No active connective tissue disease requiring medications~* No systemic autoimmune disease with visceral involvement~* No uncontrolled diabetes~* No other severe autoimmune disease~* No medical contraindication or potential problem that would preclude study compliance~PRIOR CONCURRENT THERAPY:~Biologic therapy~* More than 30 days since prior immunotherapy~* More than 30 days since prior growth factors~* More than 30 days since prior allergy shots~* No prior vaccination with any study peptides for malignancy~Chemotherapy~* More than 30 days since prior chemotherapy~Endocrine therapy~* More than 30 days since prior steroids~Radiotherapy~* More than 30 days since prior radiotherapy~Surgery~* More than 30 days since prior surgery~Other~* At least 30 days, but ≤ 24 months, since prior therapy for colorectal cancer~* No concurrent illegal drug use

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Peptide Vaccine + Montanide + GM-CSF (Type: EXPERIMENTAL): Colon peptide mixture (100 mcg each of the 4 peptides) plus 190 mcg of tetanus toxoid peptide, plus GM-CSF (110 mcg) in Montanide ISA-51 adjuvant

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Outpatient Chest Tube Management Following Thoracic Resection Improves Patient Length of Stay and Satisfaction Without Compromising Outcomes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* all patients 18-89,~* all genders,~* all patients undergoing thoracic resection,~* all patients discharged with chest tube~Exclusion Criteria:~* minors,~* all patients \> 90 years old,~* all mentally challenged,~* all non-English speaking patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: t

Study Arms:
- Outpatient chest tubes (Type: None): All patients, mixed gender, race, and age, who underwent thoracic resection by one surgeon over the past seven years and discharged home with air leak present and chest tube to portable drainage device.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Nicotine Replacement Treatment for Pregnant Smokers - 1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient's gestational age is 26 weeks or less.~* Patient is at least 16 years of age.~* Patient is able to speak English or Spanish.~* Patient intends to carry to term.~* Patient has stable residence.~* Patient has smoked five or more cigarettes everyday for the past seven days.~Exclusion Criteria:~* Evidence that the patient is pregnant with a fetus with a known congenital abnormality.~* Unstable medical problems (i.e., hyperthyroidism, temporomandibular joint disorder, pre-eclampsia, threatened abortion, hyperemesis gravidarum)~* Multiple Gestation~* Unstable psychiatric disorder~* Current drug or alcohol abuse or dependence

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: PLACEBO_COMPARATOR): placebo
- B (Type: EXPERIMENTAL): 2 mg nicotine gum

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effect of ATG-F on Engraftment, Graft Versus Host Disease (GVHD) and Graft Versus Leukemia (GVL) Effect in Haplo-identical SCT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient age 3-70 years old with a disease necessitating allogeneic SCT.~2. Patients must have a mismatched donor willing and capable of donating peripheral blood stem cells and/or bone marrow progenitor cells using conventional techniques, and lymphocytes if indicated (mismatched defined as 3/6-4/6 HLA matching).~3. Each patient / patient's guardian must sign written informed consent.~4. Patients must have an ECOG PS ≤ 2; Creatinine \<2.0 mg/dl; Ejection fraction \>40%; DLCO \>50% of predicted; Serum bilirubin \<3 gm/dl; elevated GPT or GOT \>3 x normal values.~Exclusion Criteria:~1. Not fulfilling any of the inclusion criteria.~2. Active life-threatening infection.~3. Overt untreated infection.~4. Known hypersensitivity to ATG.~5. HIV seropositivity, Hepatitis B or C antigen positivity with evidence of active hepatitis.~6. Pregnant or lactating women.~7. Donor contraindication (HIV seropositive confirmed by Western Blot Hepatitis B antigenemia; positive HCV antibodies with positive HCV PCR; evidence of bone marrow disease; unable to donate bone marrow or peripheral blood due to concurrent medical condition).~8. Inability to comply with study requirements.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): with ATG-F
- 2 (Type: NO_INTERVENTION): control

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Lansoprazole for Subgroups of Functional Dyspepsia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Dyspeptic adult outpatients~* Characteristic dyspeptic symptoms according to Rome III criteria (bothersome postprandial fullness, early satiation, epigastric pain, or epigastric burning)~* Upper gastrointestinal endoscopy excluding structural diseases~Exclusion Criteria:~* aged less than 20 years old,~* organic lesions such as peptic ulcer, tumor of any kind, stricture or structural deformity, erosive esophagitis, or vasculopathy on endoscopy~* typical and predominant reflux symptoms (heartburn or acid regurgitation)~* comorbidity with malignancy, diabetes mellitus, liver cirrhosis, renal failure, or porphyria~* history of intra-abdominal surgery~* concurrent use of aspirin, non-steroidal anti-inflammatory drug or proton pump inhibitor~* history of allergy or severe side effects to lansoprazole~* pregnant or lactating women.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- lansoprazole (Type: EXPERIMENTAL): lansoprazole 15mg (Takepron®, Takeda Pharmaceutical Company, Osaka, Japan) once daily for eight weeks
- placebo (Type: PLACEBO_COMPARATOR): placebo once daily for eight weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate Reduction of Pain in Wounds Treatment Previously Applying Lidocaine Topical Solution vs Placebo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient who has accepted and signed the informed consent before the random process.~* Patients with painful wound treatments~* Wounds or sores of any aetiology (vascular insufficiency, diabetics, traumatic, postsurgical...) that implies at minimum dermis or epidermis, it is, II to IV degree in the Spanish Classification of Sores made by the National Group to Study and Management of Pressure Ulcers and Chronic Wounds (GNEAUPP).~* Women in fertile age with pregnancy test negative.~* Men and women in fertile age using contraceptive measures~Exclusion Criteria:~* Precedents of allergic reaction to local anesthesics type amides.~* Wounds or sores degree I on the GNEAUPP Classification (without discontinuity of skin).~* Wounds or sores too large (which require more than 40 ml of solution to cover).~* Wounds around the eyes.~* Patients who presents disturbance of cardiac conduction: atrioventricular block (second or third degree) or bifascicular block~* Patients with altered level of consciousness (Glasgow Coma Scale value less than 14)~* Patients following hemodialysis, peritoneal dialysis or continuous hemofiltration treatment.~* Patients suffering moderate or severe hepatic insufficiency.~* Pregnant or lactating women.~* Patients who refuse to participate in the study.~* Patients requiring wounds treatment more than once each day.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lidocaine solution (A) (Type: ACTIVE_COMPARATOR): Two sterile gauzes will be dampen with the content of the second syringe (the content of the first syringe is always 20 ml of saline solution and it is the first sterile gauzes administrated always) that will contain 20ml of 0.5% lidocaine dilution when the wound treatment process is assigned to the letter A. The nurse has a third syringe exactly like this second syringe to apply if necessary (process still painful to the patient).
- Saline solution (B) (Type: PLACEBO_COMPARATOR): Two sterile gauzes will be dampen with the content of the second syringe (the content of the first syringe is always 20 ml of saline solution and it is the first sterile gauzes administrated always) that will contain 20ml of saline solution when the wound treatment process is assigned to the letter B. The nurse has a third syringe exactly like this second syringe to apply if necessary (process still painful to the patient). In this case, the three syringes supplied to the nurse, have saline solution.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* Male or female, ≥18 years~* Pathologically confirmed diagnosis of thymic carcinoma~* Inoperable or metastatic disease~* Had failed at least one regimen containing platinum-based combination chemotherapy for locally advanced unresectable or metastatic disease~* Baseline measurable disease~Exclusion Criteria~* Thymomas, thymolipoma, germ cell tumors, teratomas, seminomas~* Leptomeningeal metastasis or untreated active CNS (central nervous system) metastasis or leptomeningeal metastasis.~* Is currently participating and receiving an investigational drug or has participated in a study of an investigational drug within 4 weeks~* Has received other anti-tumor treatment within 4 weeks~* Major surgery for any reason, except diagnostic biopsy, within 4 weeks of the first administration of trial treatment~* Curative radiation within 3 months of the first dose of trial treatment.~* Subjects receiving immunosuppressive agents (such as steroids) for any reason should be tapered off these drugs before initiation of trial treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Thymic carcinoma (Type: EXPERIMENTAL): enrolled subjects will receive KN046 every 2 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Ibrutinib Plus Rituximab for cGVHD Following Allo-SCT

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Men and women ≥18 years old who are recipients of an allogeneic bone marrow, cord blood or peripheral blood stem cell transplant. (There will be no restrictions based upon underlying disease, donor source, degree of human leukocyte antigen (HLA) match, intensity of pre-transplant conditioning regimen or use of prior donor lymphocyte infusion(s).)~2. Chronic GVHD that is confirmed by clinical assessment and/or biopsy.~3. Either steroid-refractory or steroid-dependent cGVHD.~4. Karnofsky performance status ≥ 60.~Exclusion Criteria:~1. History of treatment with a tyrosine kinase inhibitor (eg, imatinib) or other moderate-to-significant Cyclophilin A4 inhibitor within 2 weeks of enrollment.~2. Renal insufficiency as follows: creatinine \> 2.5 mg/deciliters (dL) or Creatinine Clearance \< 30 ml/min.~3. Hepatic insufficiency as follows: serum bilirubin \>3 mg/dL or transaminitis \>3x upper limit of normal (ULN) (unless deemed due to GVHD).~4. History of cardiac dysrhythmias or known cardiovascular disease without formal Cardiology clearance.~5. History of cerebro-vascular accident or intracranial hemorrhage within 6 months prior to enrollment.~6. History of non-intracranial hemorrhage and/or coagulopathy without formal Coagulation clearance.~7. Uncontrolled infections not responsive to antibiotics, anti-viral medicines, or anti-fungal medicines; or infection requiring systemic treatment that was completed ≤14 days before enrollment.~8. History of other hematologic malignancy.~9. History of human immunodeficiency virus (HIV).~10. History of active hepatitis B virus (HBV) or hepatitis C virus (HCV) without formal Infectious Disease clearance.~11. Patients incapable of complying with routine follow up schedule or unable to be compliant with study therapy.~12. Active or within 3 months use of prohibited medications or substances (e.g., illicit drugs).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ibrutinib plus Rituximab (Type: EXPERIMENTAL): Rituximab~\*375 milligrams (mg) per meter squared intravenous infusion weekly for 4 (may repeat 8 weeks after initial therapy, if suboptimal response)~Ibrutinib~* 420 mg (140 mg capsule x3) by mouth daily~* May be given beyond 3-6 months (for maintenance).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues